Date: 2015-10-20
Type of information: R&D agreement
Compound: MAP4K4
Company: Domainex (UK) Imperial College London (UK)
Therapeutic area: Cardiovascular diseases
Type agreement: R&D
Action mechanism: protein/kinase.
Disease: myocardial infarction
Details: * On October 20, 2015, Domainex and Imperial College London announced a new partnership focused on the discovery of novel therapies to treat myocardial infarction. This follows the success of Imperial in securing £3M in funding from the Wellcome Trust Seeding Drug Discovery programme to build upon the pioneering research of Professor Michael Schneider, the British Heart Foundation Simon Marks Chair in Regenerative Cardiology. One of the key research activities of Professor Schneider’s group in Imperial’s National Heart and Lung Institute is to identify the enzyme pathways activated by cardiac stress that result in the apoptosis (programmed cell death) of cardiac muscle cells. The potential for using these findings to prevent cardiac muscle cell death following a heart attack has resulted in this research award from the Wellcome Trust. Domainex has been chosen as Imperial’s strategic drug discovery partner to provide services including biochemical and biophysical assay development, compound screening and medicinal chemistry to advance the project towards pre-clinical development. Domainex will undertake integrated lead identification and optimisation studies on the serine/threonine protein kinase enzyme target mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4). In this collaboration Domainex will seek to deliver candidate drug molecules meeting a series of defined criteria.
Financial terms:
Latest news:
